Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11392540rdf:typepubmed:Citationlld:pubmed
pubmed-article:11392540lifeskim:mentionsumls-concept:C0016011lld:lifeskim
pubmed-article:11392540lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:11392540lifeskim:mentionsumls-concept:C0332256lld:lifeskim
pubmed-article:11392540lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:11392540lifeskim:mentionsumls-concept:C0077818lld:lifeskim
pubmed-article:11392540pubmed:issue10lld:pubmed
pubmed-article:11392540pubmed:dateCreated2001-6-5lld:pubmed
pubmed-article:11392540pubmed:abstractTextThe synthesis and biological activity of novel glycoprotein IIb-IlIa anatagonists containing 3-azaspiro[5.5]undec-9-yl nucleus are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the monoazaspirocyclic structure as central template for nonpeptide RGD mimics.lld:pubmed
pubmed-article:11392540pubmed:languageenglld:pubmed
pubmed-article:11392540pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11392540pubmed:citationSubsetIMlld:pubmed
pubmed-article:11392540pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11392540pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11392540pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11392540pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11392540pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11392540pubmed:statusMEDLINElld:pubmed
pubmed-article:11392540pubmed:monthMaylld:pubmed
pubmed-article:11392540pubmed:issn0960-894Xlld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:RoseJJlld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:MehrotraM MMMlld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:HeathJJlld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:PandeyAAlld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:ScarboroughR...lld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:SmythM SMSlld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:SchottenTTlld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:RuhterGGlld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:SeroogyJJlld:pubmed
pubmed-article:11392540pubmed:authorpubmed-author:VolkotsDDlld:pubmed
pubmed-article:11392540pubmed:issnTypePrintlld:pubmed
pubmed-article:11392540pubmed:day21lld:pubmed
pubmed-article:11392540pubmed:volume11lld:pubmed
pubmed-article:11392540pubmed:ownerNLMlld:pubmed
pubmed-article:11392540pubmed:authorsCompleteYlld:pubmed
pubmed-article:11392540pubmed:pagination1293-6lld:pubmed
pubmed-article:11392540pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:meshHeadingpubmed-meshheading:11392540...lld:pubmed
pubmed-article:11392540pubmed:year2001lld:pubmed
pubmed-article:11392540pubmed:articleTitleSpirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes.lld:pubmed
pubmed-article:11392540pubmed:affiliationCOR Therapeutics, Inc, Department of Medicinal Chemistry and Biology, South San Francisco, CA 94080, USA.lld:pubmed
pubmed-article:11392540pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:11392540lld:chembl